PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced it will release its second quarter 2024 financial results and operational highlights on August 14, 2024, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update.
Interested parties can register for the conference call via a provided link, with registration recommended at least 5 minutes before the call starts. For those not planning to ask questions, listening via the webcast is suggested. Both conference call and webcast links are provided in the announcement.
PolyPid (Nasdaq: PYPD), una società biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha annunciato che rilascerà i risultati finanziari del secondo trimestre 2024 e i punti salienti operativi il 14 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda ospiterà una chiamata in conferenza e una diretta web alle 8:30 AM Eastern Time per discutere i risultati e fornire un aggiornamento aziendale.
Le parti interessate possono registrarsi per la chiamata in conferenza tramite un link fornito, con registrazione consigliata almeno 5 minuti prima dell'inizio della chiamata. Per coloro che non intendono porre domande, si suggerisce di ascoltare tramite la diretta web. Entrambi i link per la chiamata in conferenza e la diretta web sono forniti nell'annuncio.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada centrada en mejorar los resultados quirúrgicos, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y los aspectos operativos destacados el 14 de agosto de 2024, antes de la apertura de los mercados financieros de EE. UU. La empresa llevará a cabo una llamada de conferencia y una transmisión en vivo a las 8:30 AM hora del Este para discutir los resultados y proporcionar una actualización comercial.
Las partes interesadas pueden registrarse para la llamada de conferencia a través de un enlace proporcionado, recomendando registrarse al menos 5 minutos antes de que comience la llamada. Para aquellos que no planeen hacer preguntas, se sugiere escuchar a través de la transmisión en vivo. Ambos enlaces para la llamada de conferencia y la transmisión en vivo están disponibles en el anuncio.
PolyPid (Nasdaq: PYPD)은 수술 결과 개선에 중점을 둔 후기 단계의 생명공학 회사로, 2024년 2분기 재무 결과 및 운영 하이라이트를 2024년 8월 14일, 미국 금융 시장이 열리기 전에 공개할 것이라고 발표했습니다. 회사는 동부 표준시 기준 8:30 AM에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 진행합니다.
관심 있는 당사자는 제공된 링크를 통해 컨퍼런스 콜에 등록할 수 있으며, 전화를 시작하기 최소 5분 전에는 등록하는 것이 좋습니다. 질문을 할 계획이 없는 경우에는 웹캐스트를 통해 듣는 것이 좋습니다. 컨퍼런스 콜 및 웹캐스트 링크는 발표문에 제공됩니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et ses faits saillants opérationnels le 14 août 2024, avant l'ouverture des marchés financiers américains. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30 heure de l'Est pour discuter des résultats et fournir une mise à jour commerciale.
Les parties intéressées peuvent s'inscrire à la conférence téléphonique via un lien fourni, avec une inscription recommandée au moins 5 minutes avant le début de l'appel. Pour ceux qui ne prévoient pas de poser des questions, écouter via le webinaire est suggéré. Les liens pour la conférence téléphonique et le webinaire sont fournis dans l'annonce.
PolyPid (Nasdaq: PYPD), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf die Verbesserung von Operationsergebnissen konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 und operative Highlights am 14. August 2024 vor der Eröffnung der US-Finanzmärkte veröffentlichen wird. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abhalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate bereitzustellen.
Interessierte Parteien können sich über einen bereitgestellten Link für die Telefonkonferenz anmelden, wobei eine Anmeldung mindestens 5 Minuten vor Beginn der Konferenz empfohlen wird. Für diejenigen, die keine Fragen stellen möchten, wird empfohlen, über den Webcast zuzuhören. Beide Links für die Telefonkonferenz und den Webcast sind in der Ankündigung enthalten.
- None.
- None.
PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, August 14, 2024 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register.vevent.com/register/BI016c6fe17c794f8ea594d9e8bfca69f4 |
| Webcast: | https://edge.media-server.com/mmc/p/hcwb4pob |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com
FAQ
When will PolyPid (PYPD) report its Q2 2024 financial results?
What time is PolyPid's (PYPD) Q2 2024 earnings conference call?
How can I participate in PolyPid's (PYPD) Q2 2024 earnings call?
